https://news.medxy.ai/zh/75638-2/Medxy AIzh2026-09-19T08:15:17-07:00韩国患者中 USH2A 相关视网膜色素变性的独特分子与临床特征 https://news.medxy.ai/ja/75637-2/Medxy AIja2026-09-19T08:14:54-07:00韓国人患者におけるUSH2A関連網膜色素変性症の特異的な分子・臨床プロファイル https://news.medxy.ai/vi/ush2a-retinopathy-korea/Medxy AIvi2026-09-19T08:14:33-07:00Viêm sắc tố võng mạc liên quan USH2A ở bệnh nhân Hàn Quốc: Hồ sơ phân tử và lâm sàng đặc trưng, gợi mở hướng điều trị nhắm đích https://news.medxy.ai/distinct-molecular-and-clinical-profiles-of-ush2a-associated-retinitis-pigmentosa-in-korean-patients-implications-for-targeted-therapy/Medxy AIen2026-09-19T08:14:10-07:00Distinct Molecular and Clinical Profiles of USH2A-Associated Retinitis Pigmentosa in Korean Patients: Implications for Targeted Therapy https://news.medxy.ai/zh/corneal-endothelial-cell-injection/Medxy AIzh2026-09-19T08:13:26-07:00培养的人角膜内皮细胞注射后囊样黄斑水肿：发生率、危险因素与视力预后 https://news.medxy.ai/ja/75628-2/Medxy AIja2026-09-19T08:12:59-07:00培養角膜内皮細胞注入後の嚢胞様黄斑浮腫：発生率、危険因子および視力予後 https://news.medxy.ai/vi/corneal-endothelial-pseudoguttata/Medxy AIvi2026-09-19T08:12:29-07:00Phù hoàng điểm dạng nang sau tiêm tế bào nội mô giác mạc người nuôi cấy: tỷ lệ mắc, yếu tố nguy cơ và tiên lượng thị giác https://news.medxy.ai/cystoid-macular-edema-following-cultured-human-corneal-endothelial-cell-injection-incidence-risk-factors-and-visual-prognosis/Medxy AIen2026-09-19T08:12:01-07:00Cystoid Macular Edema Following Cultured Human Corneal Endothelial Cell Injection: Incidence, Risk Factors, and Visual Prognosis https://news.medxy.ai/zh/lebanon-tonsillectomy-bleeding/Medxy AIzh2026-09-19T08:11:04-07:00扁桃体切除术后出血：发生率、危险因素及对成年患者的启示 https://news.medxy.ai/ja/post-tonsillectomy-bleeding-lebanon/Medxy AIja2026-09-19T08:10:41-07:00レバノンにおける扁桃摘出術後出血：成人患者の有病率・危険因子・臨床的意義 https://news.medxy.ai/vi/post-tonsillectomy-bleeding-lebanon-2/Medxy AIvi2026-09-19T08:10:19-07:00Xuất huyết sau cắt amidan ở Liban: Tỷ lệ hiện mắc, nguy cơ và ý nghĩa đối với người bệnh trưởng thành https://news.medxy.ai/post-tonsillectomy-hemorrhage-in-lebanon-prevalence-risks-and-implications-for-adult-patients/Medxy AIen2026-09-19T08:09:55-07:00Post-Tonsillectomy Hemorrhage in Lebanon: Prevalence, Risks, and Implications for Adult Patients https://news.medxy.ai/zh/beta-trace-protein-quantification/Medxy AIzh2026-09-19T08:09:11-07:00鼻棉中β-痕迹蛋白定量：用于垂体区肿瘤经鼻内镜术后脑脊液漏早期识别的新型诊断工具 https://news.medxy.ai/ja/beta-tp-spinal-fluid-leak/Medxy AIja2026-09-19T08:08:50-07:00鼻腔スポンジ中β-TP定量で術後髄液漏を早期診断：sellar tumor内視鏡手術後の新たな検査法 https://news.medxy.ai/vi/beta-trace-protein/Medxy AIvi2026-09-19T08:08:28-07:00Định lượng Beta-Trace Protein: Công cụ chẩn đoán mới giúp phát hiện sớm rò dịch não tủy sau phẫu thuật nội soi qua mũi cho u vùng yên https://news.medxy.ai/beta-trace-protein-quantification-a-novel-diagnostic-tool-for-early-detection-of-csf-leak-post-endoscopic-endonasal-sellar-tumor-surgery/Medxy AIen2026-09-19T08:08:07-07:00Beta-Trace Protein Quantification: A Novel Diagnostic Tool for Early Detection of CSF Leak Post-Endoscopic Endonasal Sellar Tumor Surgery https://news.medxy.ai/zh/75604-2/Medxy AIzh2026-09-19T08:07:25-07:00直肠癌手术中Colovac 装置与开放式转流性袢状回肠造口术：前瞻性荟萃分析 https://news.medxy.ai/ja/75603-2/Medxy AIja2026-09-19T08:06:57-07:00直腸癌手術におけるColovacデバイスと回腸ループストーマ造設術の比較 https://news.medxy.ai/vi/colovac-vs-ileostomy/Medxy AIvi2026-09-19T08:06:28-07:00Thiết bị Colovac so với mở hồi tràng quai chuyển lưu: Phân tích gộp tiến cứu trong phẫu thuật ung thư trực tràng https://news.medxy.ai/colovac-device-vs-diverting-loop-ileostomy-a-prospective-pooled-analysis-in-rectal-cancer-surgery/Medxy AIen2026-09-19T08:06:01-07:00Colovac Device vs Diverting Loop Ileostomy: A Prospective Pooled Analysis in Rectal Cancer Surgery https://news.medxy.ai/zh/liver-transplant-risks/Medxy AIzh2026-09-19T08:05:12-07:00肝移植的非工作时间风险：识别高危时段及其对患者结局的影响 https://news.medxy.ai/ja/75595-2/Medxy AIja2026-09-19T08:04:50-07:00肝移植における勤務時間外のリスクは、患者の転帰に影響を及ぼす https://news.medxy.ai/vi/75593-2/Medxy AIvi2026-09-19T08:04:27-07:00Rủi ro trong thời gian ngoài giờ hành chính khi thực hiện ghép gan ảnh hưởng đến kết quả điều trị của bệnh nhân https://news.medxy.ai/out-of-hours-liver-transplantation-identifying-high-risk-timeframes-and-implications-for-patient-outcomes/Medxy AIen2026-09-19T08:04:02-07:00Out-of-Hours Liver Transplantation: Identifying High-Risk Timeframes and Implications for Patient Outcomes https://news.medxy.ai/zh/hpv-tp53-prognosis/Medxy AIzh2026-09-19T08:03:16-07:00HPV 与 TP53 分子分型揭示早期外阴鳞状细胞癌的预后差异 https://news.medxy.ai/ja/vulvar-cancer-stratification/Medxy AIja2026-09-19T08:02:55-07:00外陰扁平上皮癌早期症例における分子層別化：HPVとTP53の予後への影響 https://news.medxy.ai/vi/75583-2/Medxy AIvi2026-09-19T08:02:30-07:00Phân loại phân tử dựa trên HPV và TP53 cho thấy sự khác biệt về tiên lượng ở ung thư biểu mô tế bào vảy âm hộ giai đoạn sớm https://news.medxy.ai/molecular-stratification-of-early-stage-vulvar-squamous-cell-carcinoma-prognostic-impact-of-hpv-and-tp53-status/Medxy AIen2026-09-19T08:02:07-07:00Molecular Stratification of Early-Stage Vulvar Squamous Cell Carcinoma: Prognostic Impact of HPV and TP53 Status https://news.medxy.ai/zh/rhd-positive-blood/Medxy AIzh2026-09-19T08:01:19-07:00创伤患者中 RhD 阳性全血的再评估：两项随机试验后的伦理与临床启示 https://news.medxy.ai/ja/75574-2/Medxy AIja2026-09-19T08:00:56-07:00外傷患者におけるRhD陽性全血の再評価：2つの無作為化試験が示唆する倫理的および臨床的意義 https://news.medxy.ai/vi/rhd-blood-transfusion/Medxy AIvi2026-09-19T08:00:28-07:00Xem xét lại việc sử dụng máu toàn phần RhD dương tính ở bệnh nhân chấn thương còn khả năng sinh sản: hàm ý đạo đức và lâm sàng sau hai thử nghiệm ngẫu nhiên https://news.medxy.ai/reevaluating-rhd-positive-whole-blood-use-in-trauma-patients-with-reproductive-potential-ethical-and-clinical-implications-post-two-randomized-trials/Medxy AIen2026-09-19T08:00:04-07:00Reevaluating RhD-Positive Whole Blood Use in Trauma Patients with Reproductive Potential: Ethical and Clinical Implications Post-Two Randomized Trials https://news.medxy.ai/zh/perimenopause-hormone-treatment/Medxy AIzh2026-09-19T07:59:24-07:00围绝经期激素治疗怎么选：临床医生实用工具包 https://news.medxy.ai/ja/menopause-hormone-therapy-guide/Medxy AIja2026-09-19T07:59:06-07:00更年期移行期のホルモン療法をどう使い分けるか：臨床医のための実践ガイド https://news.medxy.ai/navigating-hormonal-therapies-for-perimenopause-a-practical-clinicians-toolkit/Medxy AIen2026-09-19T07:58:25-07:00Navigating Hormonal Therapies for Perimenopause: A Practical Clinician’s Toolkit https://news.medxy.ai/zh/vps13d-lipid-metabolism/Medxy AIzh2026-09-19T07:57:49-07:00VPS13D：酒精相关性脂肪性肝炎中细胞器接触位点与脂质代谢的关键调控因子 https://news.medxy.ai/ja/vps13d-alcoholic-hepatitis/Medxy AIja2026-09-19T07:57:22-07:00VPS13D：アルコール関連脂肪肝炎におけるオルガネラ接触部位と脂質代謝を制御する重要因子 https://news.medxy.ai/vi/vps13d-lipid-metabolism-2/Medxy AIvi2026-09-19T07:56:58-07:00VPS13D: Bộ điều hòa then chốt của các vị trí tiếp xúc bào quan và chuyển hóa lipid trong viêm gan nhiễm mỡ liên quan đến rượu https://news.medxy.ai/vps13d-a-crucial-regulator-of-organelle-contact-sites-and-lipid-metabolism-in-alcohol-associated-steatohepatitis/Medxy AIen2026-09-19T07:56:34-07:00VPS13D: A Crucial Regulator of Organelle Contact Sites and Lipid Metabolism in Alcohol-Associated Steatohepatitis https://news.medxy.ai/zh/tl1a-il22-crohn-treatment/Medxy AIzh2026-09-19T07:55:49-07:00揭示TL1A-LTα1β2/IL-22轴：克罗恩病伴肛周瘘管性疾病的新型治疗靶点 https://news.medxy.ai/ja/crohns-disease-treatment/Medxy AIja2026-09-19T07:55:26-07:00クローン病の肛門周囲瘻孔形成性疾患における新規治療標的：TL1A-LTα1β2/IL-22軸の全貌 https://news.medxy.ai/vi/tl1a-lt1b2-il22-crohns-treatment/Medxy AIvi2026-09-19T07:55:03-07:00Khám phá trục TL1A-LTα1β2/IL-22: Đích điều trị mới trong bệnh Crohn kèm bệnh rò quanh hậu môn https://news.medxy.ai/tl1a-il22-crohns-target/Medxy AIen2026-09-19T07:54:34-07:00Unveiling the TL1A-LTα1β2/IL-22 Axis: A New Therapeutic Target in Crohn’s Disease with Perianal Fistulising Disease https://news.medxy.ai/zh/safety-recurrence-balance/Medxy AIzh2026-09-19T07:53:50-07:00安全性与复发风险如何平衡：大型结直肠息肉冷圈套与热圈套切除术比较 https://news.medxy.ai/ja/safety-vs-recurrence/Medxy AIja2026-09-19T07:53:24-07:00安全性と再発リスクの両立をどう見るか：大腸大型ポリープに対するコールドスネア vs ホットスネア切除 https://news.medxy.ai/vi/large-colon-polyp-removal/Medxy AIvi2026-09-19T07:52:52-07:00Cân bằng giữa độ an toàn và nguy cơ tái phát: Cắt polyp đại trực tràng lớn bằng cold snare hay hot snare https://news.medxy.ai/balancing-safety-and-recurrence-cold-vs-hot-snare-resection-of-large-colorectal-polyps/Medxy AIen2026-09-19T07:52:24-07:00Balancing Safety and Recurrence: Cold vs Hot Snare Resection of Large Colorectal Polyps https://news.medxy.ai/zh/artery-spin-labeling/Medxy AIzh2026-09-19T07:51:38-07:00动脉自旋标记血流动力学指标可预测11年内认知下降与脑小血管病进展 https://news.medxy.ai/ja/75529-2/Medxy AIja2026-09-19T07:51:17-07:00動脈スピンラベリング法による血行動態評価は、11年以内の認知機能低下および脳小血管病を予測し得る https://news.medxy.ai/vi/75528-2/Medxy AIvi2026-09-19T07:50:53-07:00Các chỉ số huyết động học từ kỹ thuật Arterial Spin Labeling dự báo sự suy giảm nhận thức và tiến triển của bệnh lý mạch máu nhỏ trong suốt 11 năm https://news.medxy.ai/arterial-spin-labeling-hemodynamic-metrics-predict-cognitive-decline-and-small-vessel-disease-progression-over-11-years/Medxy AIen2026-09-19T07:50:28-07:00Arterial Spin Labeling Hemodynamic Metrics Predict Cognitive Decline and Small Vessel Disease Progression Over 11 Years https://news.medxy.ai/zh/75520-2/Medxy AIzh2026-09-19T07:49:46-07:00急性缺血性脑卒中后的住院康复与主要不良心血管事件：临床意义与证据整合 https://news.medxy.ai/ja/stroke-rehabilitation-2/Medxy AIja2026-09-19T07:49:22-07:00急性虚血性脳卒中後の入院リハビリテーションと主要有害心血管イベント：臨床的意義とエビデンスの統合 https://news.medxy.ai/inpatient-rehabilitation-and-major-adverse-cardiovascular-events-after-ischemic-stroke-clinical-implications-and-evidence-synthesis/Medxy AIen2026-09-19T07:48:25-07:00Inpatient Rehabilitation and Major Adverse Cardiovascular Events After Ischemic Stroke: Clinical Implications and Evidence Synthesis https://news.medxy.ai/zh/us-ischemic-stroke-transfer/Medxy AIzh2026-09-19T07:47:31-07:00美国缺血性卒中紧急院际转运：2016—2022年趋势与启示 https://news.medxy.ai/ja/us-ischemic-stroke-transfers/Medxy AIja2026-09-19T07:47:00-07:00米国の虚血性卒中における緊急施設間転送：2016〜2022年の動向と示唆 https://news.medxy.ai/vi/stroke-transfer-trends/Medxy AIvi2026-09-19T07:46:33-07:00Chuyển viện khẩn cấp liên cơ sở ở bệnh nhân đột quỵ thiếu máu cục bộ tại Hoa Kỳ: Xu hướng và ý nghĩa từ 2016 đến 2022 https://news.medxy.ai/emergent-interfacility-transfers-for-ischemic-stroke-in-the-u-s-patterns-and-implications-from-2016-to-2022/Medxy AIen2026-09-19T07:46:07-07:00Emergent Interfacility Transfers for Ischemic Stroke in the U.S.: Patterns and Implications from 2016 to 2022 https://news.medxy.ai/vi/easd-2026-guidelines/Medxy AIvi2026-09-19T07:43:40-07:00Hướng dẫn EASD 2026 mới: Chăm sóc thực tiễn, dựa trên bằng chứng cho diabetes distress ở người trưởng thành mắc đái tháo đường týp 1 và týp 2 https://news.medxy.ai/zh/easd-2026-diabetes-guidelines/Medxy AIzh2026-09-19T07:43:05-07:002026年EASD新指南：1型和2型糖尿病成人糖尿病困扰的实用循证管理 https://news.medxy.ai/new-2026-easd-guideline-practical-evidence-based-care-for-diabetes-distress-in-adults-with-type-1-and-type-2-diabetes/Medxy AIen2026-09-19T07:42:28-07:00New 2026 EASD Guideline: Practical, Evidence-Based Care for Diabetes Distress in Adults with Type 1 and Type 2 Diabetes https://news.medxy.ai/zh/steroid-analysis-ai/Medxy AIzh2026-09-19T07:41:28-07:00机器学习赋能类固醇谱分析：先天性肾上腺类固醇生成障碍的快速诊断新策略 https://news.medxy.ai/ja/steroid-profiling-diagnosis/Medxy AIja2026-09-19T07:41:07-07:00機械学習で精度を高めたステロイドプロファイリングによる先天性副腎ステロイド合成障害の迅速診断 https://news.medxy.ai/vi/steroid-biosynthesis-diagnostics/Medxy AIvi2026-09-19T07:40:36-07:00Hồ sơ steroid tăng cường bởi Machine Learning giúp chẩn đoán nhanh các rối loạn sinh tổng hợp steroid tuyến thượng thận bẩm sinh https://news.medxy.ai/machine-learning-enhanced-steroid-profiling-for-rapid-diagnosis-of-congenital-adrenal-steroidogenesis-disorders/Medxy AIen2026-09-19T07:40:10-07:00Machine Learning-enhanced Steroid Profiling for Rapid Diagnosis of Congenital Adrenal Steroidogenesis Disorders https://news.medxy.ai/ja/testosterone-women-children/Medxy AIja2026-09-19T07:39:25-07:00女性・小児のテストステロン基準範囲に新たな合意　2024年PCOS Challenge–CDCステークホルダー会議の成果 https://news.medxy.ai/vi/75458-2/Medxy AIvi2026-09-19T07:38:42-07:00Đạt được sự đồng thuận mới về các khoảng tham chiếu testosterone cho phụ nữ và trẻ em https://news.medxy.ai/zh/testosterone-reference-2024/Medxy AIzh2026-09-19T07:38:00-07:00女性与儿童睾酮参考区间迎来新共识：2024年PCOS Challenge–CDC利益相关方会议成果 https://news.medxy.ai/testosterone-reference-ranges/Medxy AIen2026-09-19T07:37:22-07:00New Consensus on Testosterone Reference Ranges for Females and Children: Outcomes of the 2024 PCOS Challenge–CDC Stakeholder Meeting https://news.medxy.ai/ja/weight-loss-uric-acid-management/Medxy AIja2026-09-19T07:35:54-07:00高尿酸血症男性の減量と尿酸管理：エネルギー制限DASH食・炭水化物制限食・低プリン体食の比較 https://news.medxy.ai/vi/dash-diet-weight-loss/Medxy AIvi2026-09-19T07:35:24-07:00So sánh chế độ ăn DASH hạn chế calo, chế độ ăn hạn chế carbohydrate và chế độ ăn ít purin trong giảm cân và kiểm soát urat huyết thanh ở nam giới tăng axit uric máu https://news.medxy.ai/zh/reducing-cardiogenic-shock-mortality-2/Medxy AIzh2026-09-19T07:34:13-07:00心源性休克死亡率如何降低：医院救治能力与转运策略的影响 https://news.medxy.ai/ja/reducing-cardiogenic-shock-mortality/Medxy AIja2026-09-19T07:33:52-07:00心原性ショックの死亡率を下げるには：病院機能と搬送戦略の影響 https://news.medxy.ai/vi/75446-2/Medxy AIvi2026-09-19T07:33:26-07:00Cách giảm tỷ lệ tử vong do sốc tim: Tác động của năng lực điều trị tại bệnh viện và các chiến lược vận chuyển https://news.medxy.ai/reducing-mortality-in-cardiogenic-shock-the-impact-of-hospital-capability-and-transfer-strategies/Medxy AIen2026-09-19T07:33:01-07:00Reducing Mortality in Cardiogenic Shock: The Impact of Hospital Capability and Transfer Strategies https://news.medxy.ai/zh/car-t-cardiovascular-risk-elderly/Medxy AIzh2026-09-19T07:32:17-07:00CAR-T治疗在老年人中的心血管风险：来自美国 Medicare 数据的启示 https://news.medxy.ai/ja/car-t-cardiovascular-risk/Medxy AIja2026-09-19T07:31:57-07:00高齢者におけるCAR-T療法の心血管リスク：米国Medicareデータが示す知見 https://news.medxy.ai/vi/car-t-cardiac-risk-elderly/Medxy AIvi2026-09-19T07:31:33-07:00Nguy cơ tim mạch của liệu pháp CAR-T ở người cao tuổi: phân tích từ dữ liệu Medicare Hoa Kỳ https://news.medxy.ai/cardiovascular-risks-of-car-t-therapy-in-older-adults-insights-from-us-medicare-data/Medxy AIen2026-09-19T07:31:06-07:00Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare Data https://news.medxy.ai/zh/proteomics-metabolomics-cardiotoxicity/Medxy AIzh2026-09-19T07:30:21-07:00蛋白质组学与代谢组学揭示乳腺癌心脏毒性治疗相关心脏重构的新机制 https://news.medxy.ai/ja/cardiotoxicity-breast-cancer/Medxy AIja2026-09-19T07:30:02-07:00心毒性治療を受ける乳癌患者の心リモデリングを読み解くプロテオミクス・メタボロミクス解析 https://news.medxy.ai/vi/proteomics-metabolomics-heart/Medxy AIvi2026-09-19T07:29:37-07:00Proteomics và metabolomics hé lộ cơ chế tái cấu trúc tim ở bệnh nhân ung thư vú điều trị có nguy cơ độc tính trên tim https://news.medxy.ai/proteomic-and-metabolomic-insights-into-cardiac-remodeling-in-breast-cancer-patients-undergoing-cardiotoxic-therapy/Medxy AIen2026-09-19T07:29:15-07:00Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic Therapy https://news.medxy.ai/zh/intravascular-imaging-pci/Medxy AIzh2026-09-19T07:28:33-07:00血管内影像指导PCI：更新荟萃分析证实可改善心血管结局 https://news.medxy.ai/ja/pci-optimization/Medxy AIja2026-09-19T07:28:11-07:00冠動脈内イメージングでPCIはさらに最適化できるか？ 28件のRCTメタ解析が示す心血管アウトカム改善 https://news.medxy.ai/vi/75431-2/Medxy AIvi2026-09-19T07:27:43-07:00Can thiệp mạch vành qua da (PCI) dưới hướng dẫn của hình ảnh nội mạch giúp cải thiện các kết cục tim mạch https://news.medxy.ai/intracoronary-imaging-guided-pci-updated-meta-analysis-validates-cardiovascular-outcome-benefits/Medxy AIen2026-09-19T07:27:18-07:00Intracoronary Imaging-Guided PCI: Updated Meta-Analysis Validates Cardiovascular Outcome Benefits https://news.medxy.ai/zh/rbm20-mitochondria-dysfunction/Medxy AIzh2026-09-19T07:26:34-07:00RBM20 相关扩张型心肌病的线粒体功能障碍：失调核糖核蛋白颗粒的关键作用 https://news.medxy.ai/ja/75427-2/Medxy AIja2026-09-19T07:26:12-07:00RBM20関連拡張型心筋症におけるミトコンドリア機能障害 https://news.medxy.ai/vi/75426-2/Medxy AIvi2026-09-19T07:25:49-07:00Rối loạn chức năng ty thể trong bệnh cơ tim giãn liên quan đến RBM20 https://news.medxy.ai/unraveling-mitochondrial-dysfunction-in-rbm20-related-dilated-cardiomyopathy-the-role-of-dysregulated-ribonucleoprotein-granules/Medxy AIen2026-09-19T07:25:24-07:00Unraveling Mitochondrial Dysfunction in RBM20-Related Dilated Cardiomyopathy: The Role of Dysregulated Ribonucleoprotein Granules https://news.medxy.ai/zh/ccnd1-pdk4-axis/Medxy AIzh2026-09-19T07:24:36-07:00靶向 CCND1-PDK4 轴促进修复型巨噬细胞表型并减轻心肌梗死后心脏重构 https://news.medxy.ai/ja/ccnd1-pdk4-cardiac-remodeling/Medxy AIja2026-09-19T07:24:12-07:00CCND1-PDK4軸を標的とした修復型マクロファージ誘導による心筋梗塞後心リモデリング抑制 https://news.medxy.ai/vi/ccnd1-pdk4-macrophage/Medxy AIvi2026-09-19T07:23:44-07:00Nhắm trục CCND1-PDK4 để thúc đẩy kiểu hình đại thực bào có tính sửa chữa và hạn chế tái cấu trúc tim sau nhồi máu cơ tim https://news.medxy.ai/targeting-the-ccnd1-pdk4-axis-to-promote-reparative-macrophage-phenotype-and-mitigate-post-myocardial-infarction-cardiac-remodeling/Medxy AIen2026-09-19T07:23:18-07:00Targeting the CCND1-PDK4 Axis to Promote Reparative Macrophage Phenotype and Mitigate Post-Myocardial Infarction Cardiac Remodeling https://news.medxy.ai/zh/acute-kidney-injury-markers/Medxy AIzh2026-09-18T11:53:49-07:00重症患者急性肾损伤新型生物标志物：证据图谱全景解读 https://news.medxy.ai/ja/75094-2/Medxy AIja2026-09-18T11:53:27-07:00重症患者における急性腎障害の新規バイオマーカー https://news.medxy.ai/vi/75092-2/Medxy AIvi2026-09-18T11:53:07-07:00Các dấu ấn sinh học mới đối với tổn thương thận cấp ở bệnh nhân nguy kịch https://news.medxy.ai/unlocking-the-potential-of-novel-biomarkers-for-acute-kidney-injury-in-the-critically-ill-a-comprehensive-evidence-mapping/Medxy AIen2026-09-18T11:52:49-07:00Unlocking the Potential of Novel Biomarkers for Acute Kidney Injury in the Critically Ill: A Comprehensive Evidence Mapping https://news.medxy.ai/zh/value-based-payment-impact/Medxy AIzh2026-09-18T11:52:04-07:00基于相对价值单位计酬对急诊医师绩效与运营结局影响的评估 https://news.medxy.ai/ja/rvu-based-payments-impact/Medxy AIja2026-09-18T11:51:47-07:00救急医師のRVUベース報酬は現場を変えるか――生産性と運営指標への影響を検証 https://news.medxy.ai/vi/rvu-impact-efficiency/Medxy AIvi2026-09-18T11:51:23-07:00Chi trả theo RVU ảnh hưởng thế nào đến hiệu suất bác sĩ cấp cứu và kết quả vận hành? https://news.medxy.ai/evaluating-the-impact-of-relative-value-unit-based-compensation-on-emergency-physician-performance-and-operational-outcomes/Medxy AIen2026-09-18T11:51:02-07:00Evaluating the Impact of Relative Value Unit-Based Compensation on Emergency Physician Performance and Operational Outcomes https://news.medxy.ai/ja/smart-bedside-station-factors/Medxy AIja2026-09-18T11:50:19-07:00入院患者のSmart Bedside Station利用を左右する要因とは：UTAUTに基づく質的研究 https://news.medxy.ai/vi/smart-bed-system-factors/Medxy AIvi2026-09-18T11:50:00-07:00Các yếu tố thúc đẩy và rào cản khi sử dụng hệ thống Trạm đầu giường thông minh ở người bệnh nội trú: Nghiên cứu định tính dựa trên UTAUT https://news.medxy.ai/facilitators-and-barriers-of-using-smart-bedside-station-systems-among-hospitalized-patients-a-qualitative-study-based-on-utaut/Medxy AIen2026-09-18T11:49:39-07:00Facilitators and Barriers of Using Smart Bedside Station Systems Among Hospitalized Patients: A Qualitative Study Based on UTAUT https://news.medxy.ai/zh/cancer-palliative-care/Medxy AIzh2026-09-18T11:49:01-07:00优化癌症患者临终关怀转衔：来自多中心定性与定量证据的启示 https://news.medxy.ai/ja/75063-2/Medxy AIja2026-09-18T11:48:41-07:00がん患者のターミナルケアにおける移行の最適化 https://news.medxy.ai/vi/75061-2/Medxy AIvi2026-09-18T11:48:17-07:00Tối ưu hóa quá trình chuyển tiếp sang chăm sóc cuối đời cho bệnh nhân ung thư https://news.medxy.ai/optimizing-palliative-care-for-effective-hospice-transitions-in-cancer-patients-insights-from-multicenter-qualitative-and-quantitative-evidence/Medxy AIen2026-09-18T11:47:54-07:00Optimizing Palliative Care for Effective Hospice Transitions in Cancer Patients: Insights from Multicenter Qualitative and Quantitative Evidence https://news.medxy.ai/ja/ckd-anemia-guide/Medxy AIja2026-09-18T11:46:56-07:00CKDの貧血に関するKDIGO 2026：臨床医のための主要推奨と実践ガイド https://news.medxy.ai/vi/anemia-ckd-kdigo-2026/Medxy AIvi2026-09-18T11:46:23-07:00Thiếu máu trong CKD theo KDIGO 2026: các khuyến nghị cốt lõi và hướng dẫn thực hành cho lâm sàng viên https://news.medxy.ai/zh/ckd-anemia-guidelines/Medxy AIzh2026-09-18T11:45:50-07:00KDIGO 2026 CKD 贫血指南要点：临床医师实用解读 https://news.medxy.ai/kdigo-2026-on-anemia-in-ckd-key-recommendations-and-practical-guidance-for-clinicians/Medxy AIen2026-09-18T11:45:23-07:00KDIGO 2026 on Anemia in CKD: Key Recommendations and Practical Guidance for Clinicians https://news.medxy.ai/zh/sickle-cell-stem-cell-mobilization/Medxy AIzh2026-09-18T11:44:20-07:00镰状细胞病自体备用干细胞动员优化：GCSF联合plerixafor的应用及其对基因治疗的启示 https://news.medxy.ai/ja/75038-2/Medxy AIja2026-09-18T11:44:02-07:00鎌状赤血球症における自家幹細胞動員の最適化：G-CSFとプレリキサホールの併用および遺伝子治療への示唆 https://news.medxy.ai/vi/stem-cell-mobilization/Medxy AIvi2026-09-18T11:43:43-07:00Tối ưu hóa huy động tế bào gốc tự thân dự phòng bằng GCSF và plerixafor trong bệnh hồng cầu hình liềm: Hàm ý cho liệu pháp gen https://news.medxy.ai/optimizing-autologous-stem-cell-backup-mobilization-with-gcsf-and-plerixafor-in-sickle-cell-disease-implications-for-gene-therapy/Medxy AIen2026-09-18T11:43:23-07:00Optimizing Autologous Stem Cell Backup Mobilization with GCSF and Plerixafor in Sickle Cell Disease: Implications for Gene Therapy https://news.medxy.ai/zh/oral-ixazomib-pomalidomide-dexamethasone/Medxy AIzh2026-09-18T11:42:42-07:00全口服伊沙佐米、泊马度胺联合地塞米松治疗三药类暴露多发性骨髓瘤的疗效与安全性：来自II期研究的启示 https://news.medxy.ai/ja/oral-ixazomib-therapy/Medxy AIja2026-09-18T11:42:22-07:00三剤クラス曝露多発性骨髄腫に対する全経口イキサゾミブ・ポマリドミド・デキサメタゾン療法の有効性と安全性：第II相試験からの示唆 https://news.medxy.ai/vi/ixazomib-pomalidomide-dexamethasone/Medxy AIvi2026-09-18T11:42:04-07:00Hiệu quả và tính an toàn của phác đồ uống hoàn toàn ixazomib, pomalidomide và dexamethasone ở đa u tủy xương đã phơi nhiễm với ba nhóm thuốc: Nhận định từ nghiên cứu giai đoạn II https://news.medxy.ai/efficacy-and-safety-of-all-oral-ixazomib-pomalidomide-and-dexamethasone-in-triple-class-exposed-multiple-myeloma-insights-from-a-phase-ii-study/Medxy AIen2026-09-18T11:41:43-07:00Efficacy and Safety of All-Oral Ixazomib, Pomalidomide, and Dexamethasone in Triple-Class Exposed Multiple Myeloma: Insights from a Phase II Study https://news.medxy.ai/zh/bcr-abl1-treatment/Medxy AIzh2026-09-18T11:40:53-07:00阿西米尼为 BCR::ABL1 T315I 突变型慢性髓性白血病提供有力治疗选择：Ⅰ期试验最终结果 https://news.medxy.ai/ja/75013-2/Medxy AIja2026-09-18T11:40:36-07:00アシミニブはBCR::ABL1 T315I変異型慢性骨髄性白血病に対する有力な治療選択肢となる：第I相試験の最終結果 https://news.medxy.ai/vi/75011-2/Medxy AIvi2026-09-18T11:40:15-07:00Asciminib mang lại một lựa chọn điều trị hiệu quả cho bệnh bạch cầu tủy mạn tính có đột biến BCR::ABL1 T315I https://news.medxy.ai/asciminib-as-a-robust-treatment-option-for-bcrabl1-t315i-mutated-chronic-myeloid-leukemia-final-phase-1-trial-outcomes/Medxy AIen2026-09-18T11:39:56-07:00Asciminib as a Robust Treatment Option for BCR::ABL1 T315I-Mutated Chronic Myeloid Leukemia: Final Phase 1 Trial Outcomes https://news.medxy.ai/zh/nk-cells-ifn-activation/Medxy AIzh2026-09-18T11:39:11-07:00激活Ⅰ型干扰素的 NK 细胞：真性红细胞增多症免疫治疗的新策略 https://news.medxy.ai/ja/nk-cell-activation-therapy/Medxy AIja2026-09-18T11:38:50-07:00第I型インターフェロンで活性化されるNK細胞を活用する：真性多血症に対する新たな免疫治療戦略 https://news.medxy.ai/vi/nk-cell-therapy/Medxy AIvi2026-09-18T11:38:23-07:00Khai thác tế bào NK được hoạt hóa bởi interferon type I: hướng miễn dịch trị liệu mới cho đa hồng cầu nguyên phát https://news.medxy.ai/harnessing-type-i-interferon-activated-nk-cells-a-novel-immunotherapeutic-approach-to-polycythemia-vera/Medxy AIen2026-09-18T11:38:01-07:00Harnessing Type-I Interferon-Activated NK Cells: A Novel Immunotherapeutic Approach to Polycythemia Vera https://news.medxy.ai/zh/eosinophil-count-asthma/Medxy AIzh2026-09-18T11:37:14-07:00Rademikibart与中重度哮喘中的嗜酸性粒细胞计数：来自2b期随机试验的启示 https://news.medxy.ai/ja/rademikibart-eosinophils-asthma-2/Medxy AIja2026-09-18T11:36:53-07:00中等症から重症喘息におけるRademikibartと好酸球数：第2b相無作為化試験からの知見 https://news.medxy.ai/vi/rademikibart-eosinophils-asthma/Medxy AIvi2026-09-18T11:36:29-07:00Rademikibart và số lượng bạch cầu ái toan trong hen phế quản mức độ trung bình đến nặng: Góc nhìn từ thử nghiệm ngẫu nhiên pha 2b https://news.medxy.ai/rademikibart-and-eosinophil-counts-in-moderate-to-severe-asthma-insights-from-a-phase-2b-randomized-trial/Medxy AIen2026-09-18T11:36:05-07:00Rademikibart and Eosinophil Counts in Moderate-to-Severe Asthma: Insights from a Phase 2b Randomized Trial https://news.medxy.ai/zh/pseudomonas-subtypes-2/Medxy AIzh2026-09-18T11:35:17-07:00解读铜绿假单胞菌亚型：支气管扩张症临床差异的意义 https://news.medxy.ai/ja/pseudomonas-subtypes/Medxy AIja2026-09-18T11:34:59-07:00気管支拡張症における緑膿菌サブタイプを読み解く：臨床的不均一性への示唆 https://news.medxy.ai/vi/pseudomonas-aeruginosa-subgroups/Medxy AIvi2026-09-18T11:34:37-07:00Giải mã các phân nhóm <i>Pseudomonas aeruginosa</i>: Ý nghĩa đối với sự khác biệt lâm sàng trong giãn phế quản https://news.medxy.ai/decoding-pseudomonas-aeruginosa-subtypes-implications-for-clinical-variability-in-bronchiectasis/Medxy AIen2026-09-18T11:34:17-07:00Decoding Pseudomonas aeruginosa Subtypes: Implications for Clinical Variability in Bronchiectasis https://news.medxy.ai/zh/wavelight-lasik-outcomes/Medxy AIzh2026-09-18T11:33:33-07:00WaveLight Plus InnovEyes 射线追踪引导 LASIK 1 年结局：近视与近视性散光的精准屈光矫正 https://news.medxy.ai/ja/74992-2/Medxy AIja2026-09-18T11:33:11-07:00WaveLight Plus InnovEyes レイトレーシング・ガイデッドLASIKの1年後の成績 https://news.medxy.ai/vi/lasik-raytracing-results/Medxy AIvi2026-09-18T11:32:48-07:00Kết quả sau 1 năm của LASIK dẫn đường bằng ray-tracing WaveLight Plus InnovEyes: Hiệu chỉnh khúc xạ chính xác cho cận thị và loạn thị cận thị https://news.medxy.ai/one-year-outcomes-of-wavelight-plus-innoveyes-ray-tracing-guided-lasik-precision-refractive-correction-for-myopia-and-myopic-astigmatism/Medxy AIen2026-09-18T11:32:27-07:00One-Year Outcomes of WaveLight Plus InnovEyes Ray-Tracing-Guided LASIK: Precision Refractive Correction for Myopia and Myopic Astigmatism https://news.medxy.ai/zh/tonsil-pathology-checks/Medxy AIzh2026-09-18T11:31:36-07:00安全网医院常规扁桃体病理检查是否必要？低检出率支持风险分层策略 https://news.medxy.ai/ja/tonsil-pathology-utility/Medxy AIja2026-09-18T11:31:18-07:00安全網医療機関における定期的な扁桃病理検査の有用性を再考する：予期せぬ悪性腫瘍の検出率は低く、リスク層別化アプローチを支持 https://news.medxy.ai/vi/routine-tonsil-pathology/Medxy AIvi2026-09-18T11:30:57-07:00Giải phẫu bệnh amidan thường quy có thực sự cần thiết? Bằng chứng từ bệnh viện an sinh cho thấy tỷ lệ phát hiện ác tính bất ngờ rất thấp https://news.medxy.ai/evaluating-the-utility-of-routine-tonsil-pathology-in-a-safety-net-hospital-low-yield-of-unexpected-malignancies-supports-risk-stratified-approach/Medxy AIen2026-09-18T11:30:38-07:00Evaluating the Utility of Routine Tonsil Pathology in a Safety-Net Hospital: Low Yield of Unexpected Malignancies Supports Risk-Stratified Approach https://news.medxy.ai/zh/74983-2/Medxy AIzh2026-09-18T11:30:00-07:00早发型大肠癌的发病率仍在上升，且存在种族差异 https://news.medxy.ai/ja/colorectal-cancer-disparities/Medxy AIja2026-09-18T11:29:37-07:00大腸内視鏡検査は増えても続く若年発症大腸癌の増加と人種格差 https://news.medxy.ai/rising-early-onset-colorectal-cancer-and-persistent-racial-disparities-despite-increased-colonoscopy-use/Medxy AIen2026-09-18T11:28:47-07:00Rising Early-Onset Colorectal Cancer and Persistent Racial Disparities Despite Increased Colonoscopy Use https://news.medxy.ai/zh/imas-liver-transplant-2/Medxy AIzh2026-09-18T11:27:54-07:00综合肌肉-脂肪评分（IMAS）：提升肝移植后性别敏感性预后评估 https://news.medxy.ai/ja/imas-liver-transplant/Medxy AIja2026-09-18T11:27:36-07:00筋・脂肪を統合した新指標IMAS：肝移植後予後予測を性別に最適化する https://news.medxy.ai/vi/imas-liver-transplant-prognosis/Medxy AIvi2026-09-18T11:27:15-07:00IMAS: Điểm số cơ–mô mỡ tích hợp mở ra hướng tiên lượng sau ghép gan nhạy cảm với giới https://news.medxy.ai/integrative-muscle-adipose-score-imas-enhancing-sex-sensitive-prognostication-after-liver-transplantation/Medxy AIen2026-09-18T11:26:55-07:00Integrative Muscle-Adipose Score (IMAS): Enhancing Sex-Sensitive Prognostication After Liver Transplantation https://news.medxy.ai/zh/activate-quinolinic-acid/Medxy AIzh2026-09-18T11:26:19-07:00激活犬尿喹啉酸与脑肠轴：促进卒中恢复的新策略 https://news.medxy.ai/ja/stroke-recovery/Medxy AIja2026-09-18T11:25:58-07:00キヌレン酸と腸脳軸を活用した脳卒中回復促進 https://news.medxy.ai/vi/kynurenic-acid-stroke/Medxy AIvi2026-09-18T11:25:34-07:00Khai thác acid kynurenic và trục ruột-não để cải thiện hồi phục sau đột quỵ https://news.medxy.ai/harnessing-kynurenic-acid-and-the-gut-brain-axis-to-improve-stroke-recovery/Medxy AIen2026-09-18T11:25:14-07:00Harnessing Kynurenic Acid and the Gut-Brain Axis to Improve Stroke Recovery https://news.medxy.ai/zh/sglt2-stroke-recovery-2/Medxy AIzh2026-09-18T11:24:32-07:00糖尿病卒中患者接受血管内血栓切除术后使用SGLT2抑制剂可促进恢复：一项多中心回顾性研究 https://news.medxy.ai/ja/sglt2-stroke-recovery/Medxy AIja2026-09-18T11:24:13-07:00糖尿病性脳卒中患者の血管内血栓除去療法後回復をSGLT2阻害薬が後押し：多施設後ろ向き研究 https://news.medxy.ai/vi/sglt2-inhibitors-stroke-recovery/Medxy AIvi2026-09-18T11:23:52-07:00Chất ức chế SGLT2 giúp cải thiện hồi phục sau lấy huyết khối nội mạch ở bệnh nhân đột quỵ đái tháo đường: Nghiên cứu hồi cứu đa trung tâm https://news.medxy.ai/sglt2-inhibitors-enhance-recovery-after-endovascular-thrombectomy-in-diabetic-stroke-patients-a-multicenter-retrospective-study/Medxy AIen2026-09-18T11:23:31-07:00SGLT2 Inhibitors Enhance Recovery After Endovascular Thrombectomy in Diabetic Stroke Patients: A Multicenter Retrospective Study https://news.medxy.ai/zh/fenofibrate-diabetic-retinopathy-2/Medxy AIzh2026-09-18T11:22:45-07:00非诺贝特使用与2型糖尿病视力威胁性糖尿病视网膜病变风险降低：来自英国真实世界数据的启示 https://news.medxy.ai/ja/74942-2/Medxy AIja2026-09-18T11:22:28-07:00フェノフィブラートの使用と2型糖尿病における視力を脅かす糖尿病網膜症のリスク低下 https://news.medxy.ai/vi/fenofibrate-diabetic-retinopathy/Medxy AIvi2026-09-18T11:22:05-07:00Fenofibrate làm giảm nguy cơ bệnh võng mạc đái tháo đường đe dọa thị lực ở đái tháo đường type 2: Bằng chứng từ dữ liệu thực tế tại Vương quốc Anh https://news.medxy.ai/fenofibrate-use-and-reduced-risk-of-sight-threatening-diabetic-retinopathy-in-type-2-diabetes-insights-from-uk-real-world-data/Medxy AIen2026-09-18T11:21:44-07:00Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World Data https://news.medxy.ai/zh/ivus-pci-east-asia/Medxy AIzh2026-09-18T11:21:06-07:00IVUS引导PCI疗效为何存在地域差异？随机试验荟萃分析揭示东亚获益更显著 https://news.medxy.ai/ja/ivus-pci-regional%e5%b7%ae/Medxy AIja2026-09-18T11:20:46-07:00IVUSガイド下PCIの成績にみられる地域差：ランダム化試験メタ解析からの示唆 https://news.medxy.ai/vi/regional-pci-outcomes/Medxy AIvi2026-09-18T11:20:24-07:00Khác biệt theo khu vực về kết cục của PCI được hướng dẫn bằng IVUS so với hướng dẫn bằng chụp mạch: Góc nhìn từ phân tích gộp các thử nghiệm ngẫu nhiên https://news.medxy.ai/geographic-variability-in-outcomes-of-ivus-guided-versus-angiography-guided-pci-insights-from-a-meta-analysis-of-randomized-trials/Medxy AIen2026-09-18T11:20:04-07:00Geographic Variability in Outcomes of IVUS-Guided Versus Angiography-Guided PCI: Insights from a Meta-Analysis of Randomized Trials https://news.medxy.ai/zh/mybpc3-mutations/Medxy AIzh2026-09-18T11:19:09-07:00揭开隐匿性 MYBPC3 变异之谜：放大错剪接并致肥厚型心肌病 https://news.medxy.ai/ja/mybpc3-mutation-cardiomyopathy/Medxy AIja2026-09-18T11:18:47-07:00肥大型心筋症の鍵を握るMYBPC3潜在変異：ミススプライシング増幅の正体 https://news.medxy.ai/vi/74927-2/Medxy AIvi2026-09-18T11:18:25-07:00Các biến thể gen MYBPC3 có thể gây bệnh cơ tim phì đại https://news.medxy.ai/unveiling-a-cryptic-mybpc3-variant-amplifying-missplicing-in-hypertrophic-cardiomyopathy/Medxy AIen2026-09-18T11:18:01-07:00Unveiling a Cryptic MYBPC3 Variant Amplifying Missplicing in Hypertrophic Cardiomyopathy https://news.medxy.ai/zh/aml-preconditioning-options/Medxy AIzh2026-09-18T11:05:07-07:00AML清髓性预处理新选择：曲奥磺舒联合氟达拉滨在中年患者中的应用前景 https://news.medxy.ai/ja/treosulfan-fludarabine-aml/Medxy AIja2026-09-18T11:04:45-07:00AMLにおける骨髄破壊的 Treosulfan-Fludarabine 前処置を検証する：中年成人に有望な代替選択肢 https://news.medxy.ai/vi/myeloablative-conditioning-aml/Medxy AIvi2026-09-18T11:04:19-07:00Đánh giá phác đồ điều kiện hóa myeloablative treosulfan-fludarabine trong AML: một lựa chọn thay thế đầy hứa hẹn cho người trưởng thành trung niên https://news.medxy.ai/evaluating-myeloablative-treosulfan-fludarabine-conditioning-in-aml-a-promising-alternative-for-middle-aged-adults/Medxy AIen2026-09-18T11:03:57-07:00Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged Adults https://news.medxy.ai/zh/pediatric-bcell-receptor-maturation/Medxy AIzh2026-09-18T11:03:00-07:00儿科造血干细胞移植后B细胞受体库如何逐步成熟：早期免疫重建的新认识 https://news.medxy.ai/ja/74890-2/Medxy AIja2026-09-18T11:02:34-07:00小児における造血幹細胞移植後のB細胞受容体レパートリーの経時的成熟：早期免疫再構築に関する示唆 https://news.medxy.ai/vi/b-cell-receptor-development/Medxy AIvi2026-09-18T11:02:11-07:00Quá trình trưởng thành dần của kho thụ thể tế bào B sau ghép tế bào gốc tạo máu ở trẻ em: gợi ý về tái tạo miễn dịch giai đoạn sớm https://news.medxy.ai/gradual-maturation-of-the-b-cell-receptor-repertoire-after-pediatric-hematopoietic-stem-cell-transplantation-insights-into-early-immune-reconstitution/Medxy AIen2026-09-18T11:01:50-07:00Gradual Maturation of the B-Cell Receptor Repertoire After Pediatric Hematopoietic Stem Cell Transplantation: Insights into Early Immune Reconstitution https://news.medxy.ai/zh/bendamustine-t-cell-leukemia/Medxy AIzh2026-09-18T11:00:47-07:00苯达莫司汀作为高肿瘤负荷 T 细胞大颗粒淋巴细胞白血病的新型单药治疗：临床疗效与 STAT3 通路抑制 https://news.medxy.ai/ja/bendamustine-stat3-leukemia/Medxy AIja2026-09-18T11:00:24-07:00高腫瘍量T細胞大型顆粒リンパ球性白血病に対するBendamustine単剤療法：臨床効果とSTAT3経路阻害 https://news.medxy.ai/vi/bendamustine-treatment/Medxy AIvi2026-09-18T10:59:55-07:00Bendamustine: hướng điều trị đơn trị liệu mới đầy triển vọng cho T-cell large granular lymphocytic leukemia gánh nặng cao https://news.medxy.ai/bendamustine-as-a-novel-single-agent-therapy-in-high-burden-t-cell-large-granular-lymphocytic-leukemia-clinical-efficacy-and-stat3-pathway-inhibition/Medxy AIen2026-09-18T10:59:37-07:00Bendamustine as a Novel Single-Agent Therapy in High Burden T-Cell Large Granular Lymphocytic Leukemia: Clinical Efficacy and STAT3 Pathway Inhibition https://news.medxy.ai/zh/functional-immune-typing-prediction/Medxy AIzh2026-09-18T10:58:40-07:00用功能性免疫分型预测多发性骨髓瘤免疫治疗应答 https://news.medxy.ai/ja/multiple-myeloma-immunotherapy/Medxy AIja2026-09-18T10:58:13-07:00多発性骨髄腫免疫療法の応答予測に挑む機能的免疫プロファイリング https://news.medxy.ai/vi/immunotherapy-response-prediction/Medxy AIvi2026-09-18T10:57:44-07:00Khai thác phân tích miễn dịch chức năng để dự đoán đáp ứng trong miễn dịch trị liệu đa u tủy xương https://news.medxy.ai/leveraging-functional-immune-profiling-to-predict-response-in-myeloma-immunotherapy/Medxy AIen2026-09-18T10:57:23-07:00Leveraging Functional Immune Profiling to Predict Response in Myeloma Immunotherapy https://news.medxy.ai/zh/xmab18968-therapy-aml-tall/Medxy AIzh2026-09-18T10:56:38-07:00靶向 CD38 的创新双特异性抗体 XmAb18968：复发/难治性 AML 与 T-ALL 的治疗新希望 https://news.medxy.ai/ja/74865-2/Medxy AIja2026-09-18T10:56:20-07:00XmAb18968：再発・難治性AMLおよびT-ALL治療の新たな希望 https://news.medxy.ai/vi/74864-2/Medxy AIvi2026-09-18T10:55:53-07:00XmAb18968: Hy vọng mới trong điều trị AML và T-ALL tái phát/kháng trị https://news.medxy.ai/innovative-cd38-targeted-bispecific-antibody-xmab18968-shows-promise-in-relapsed-refractory-aml-and-t-all/Medxy AIen2026-09-18T10:55:31-07:00Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALL https://news.medxy.ai/zh/lisocabtagene-survival-2/Medxy AIzh2026-09-18T10:54:31-07:00Lisocabtagene maraleucel在复发/难治性大B细胞淋巴瘤中的5年生存与持久缓解：TRANSCEND NHL 001研究启示 https://news.medxy.ai/ja/liso-cel-survival-transcend/Medxy AIja2026-09-18T10:54:07-07:00再発・難治性大細胞型B細胞リンパ腫におけるliso-celの5年生存と持続寛解：TRANSCEND NHL 001試験からの知見 https://news.medxy.ai/vi/lisocabtagene-survival/Medxy AIvi2026-09-18T10:53:48-07:00Lisocabtagene maraleucel mang lại sống còn 5 năm và lui bệnh bền vững trong u lympho tế bào B lớn tái phát/kháng trị: Góc nhìn từ nghiên cứu TRANSCEND NHL 001 https://news.medxy.ai/five-year-survival-and-durable-remission-with-lisocabtagene-maraleucel-in-relapsed-refractory-large-b-cell-lymphoma-insights-from-the-transcend-nhl-001-study/Medxy AIen2026-09-18T10:53:29-07:00Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study